SG11201804860YA - Crystalline forms of thienopyrimidine compound - Google Patents
Crystalline forms of thienopyrimidine compoundInfo
- Publication number
- SG11201804860YA SG11201804860YA SG11201804860YA SG11201804860YA SG11201804860YA SG 11201804860Y A SG11201804860Y A SG 11201804860YA SG 11201804860Y A SG11201804860Y A SG 11201804860YA SG 11201804860Y A SG11201804860Y A SG 11201804860YA SG 11201804860Y A SG11201804860Y A SG 11201804860YA
- Authority
- SG
- Singapore
- Prior art keywords
- hwaseong
- gyeonggi
- international
- dongtangiheung
- crystalline forms
- Prior art date
Links
- -1 thienopyrimidine compound Chemical class 0.000 title abstract 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111011101111011011111111001111101111011111 International Bureau ... .1 j ..... .....1 (10) International Publication Number (43) International Publication Date WO 2017/116193 Al 6 July 2017 (06.07.2017) WI P0 I P CT (51) International Patent Classification: (74) Agent: Y.P.LEE, MOCK & PARTNERS; 12F Daelim C07D 495/04 (2006.01) Acrotel, 13 Eonju-ro 30-gil, Gangnam-gu, Seoul 06292 (KR). (21) International Application Number: PCT/KR2016/015536 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, 30 December 2016 (30.12.2016) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (25) Filing Language: English DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (26) Publication Language: English KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (30) Priority Data: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 10-2015-0190854 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, 31 December 2015 (31.12.2015) KR RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (71) Applicant: HANMI PHARM. CO ., LTD. [KR/KR]; 214, ZA, ZM, ZW. Muha-ro, Paltan-myeon, Hwaseong-si, Gyeonggi-do 18536 (KR). (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (72) Inventors: JUNG, Jae Hyuk; 550, Dongtangiheung-ro, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Hwaseong-si, Gyeonggi-do 18469 (KR). BAEK, Jong TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Ouk; 550, Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 18469 (KR). JUNG, Sun Young; 550, Dongtangi- DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, heung-ro, Hwaseong-si, Gyeonggi-do 18469 (KR). LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, KWAK, Eun Joo; 550, Dongtangiheung-ro, Hwaseong-si, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Gyeonggi-do 18469 (KR). KIM, Hee Cheol; 550, GW, KM, ML, MR, NE, SN, TD, TG). Dongtangiheung-ro, Hwaseong-si, Gyeonggi-do 18469 (KR). HA, Tae Hee; 550, Dongtangiheung-ro, Hwaseong- Published: si, Gyeonggi-do 18469 (KR). — with international search report (Art. 21(3)) (54) Title: CRYSTALLINE FORMS OF THIENOPYRIMIDINE COMPOUND - 2000 175 - 2 :' g 1000-: _ en _ C:7 Il 1-1 1-1 IN 1-1 (57) : The present invention 0 d]pyrimidin-4-yloxy)phenyl)acrylamide, \" used for the preparation of a pharmaceutical 111111111111 11111111111 1 111 I 111 I 1 10 20 30 40 2Theta (Degree) relates to crystalline forms of N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2- and pharmaceutical compositions containing the same. The crystalline composition containing the same as an active ingredient. forms can be easily
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20150190854 | 2015-12-31 | ||
| PCT/KR2016/015536 WO2017116193A1 (en) | 2015-12-31 | 2016-12-30 | Crystalline forms of thienopyrimidine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201804860YA true SG11201804860YA (en) | 2018-07-30 |
Family
ID=59225209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201804860YA SG11201804860YA (en) | 2015-12-31 | 2016-12-30 | Crystalline forms of thienopyrimidine compound |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10464946B2 (en) |
| EP (1) | EP3380482A4 (en) |
| JP (1) | JP2019504046A (en) |
| KR (1) | KR20180089904A (en) |
| CN (1) | CN108473507A (en) |
| AU (1) | AU2016382385A1 (en) |
| BR (1) | BR112018013364A2 (en) |
| CA (1) | CA3010315A1 (en) |
| HK (1) | HK1252842A1 (en) |
| IL (1) | IL259982A (en) |
| MX (1) | MX2018008005A (en) |
| PH (1) | PH12018501331A1 (en) |
| RU (1) | RU2018122825A (en) |
| SG (1) | SG11201804860YA (en) |
| TW (1) | TW201726686A (en) |
| WO (1) | WO2017116193A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20170050453A (en) * | 2015-10-30 | 2017-05-11 | 한미약품 주식회사 | Novel process for preparing thienopyrimidine compound and intermediates used therein |
| AU2016382384A1 (en) * | 2015-12-31 | 2018-07-12 | Hanmi Pharm. Co., Ltd. | Crystalline forms of hydrochloride salts of thienopyrimidine compound |
| KR20200114776A (en) * | 2019-03-29 | 2020-10-07 | 한미약품 주식회사 | Crystalline forms of acid addition salts of furopyrimidine compound |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012033253A2 (en) * | 2010-06-23 | 2016-11-22 | Hanmi Science Co Ltd | novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
| WO2015112705A2 (en) * | 2014-01-24 | 2015-07-30 | Clovis Oncology, Inc. | Therapeutic combinations for treating cancer |
| TW201622744A (en) * | 2014-03-04 | 2016-07-01 | 美國禮來大藥廠 | Combination therapy for cancer |
| WO2016025641A1 (en) * | 2014-08-13 | 2016-02-18 | Celgene Avilomics Research, Inc. | Combinations of an erk inhibitor and an egfr inhibitor and related methods |
| CN107108649B (en) * | 2014-12-30 | 2019-08-09 | 韩美药品株式会社 | Be used to prepare Thienopyrimidine compound novel method and its used in intermediate |
| KR20170050453A (en) * | 2015-10-30 | 2017-05-11 | 한미약품 주식회사 | Novel process for preparing thienopyrimidine compound and intermediates used therein |
-
2016
- 2016-12-30 WO PCT/KR2016/015536 patent/WO2017116193A1/en active Application Filing
- 2016-12-30 MX MX2018008005A patent/MX2018008005A/en unknown
- 2016-12-30 CA CA3010315A patent/CA3010315A1/en not_active Abandoned
- 2016-12-30 BR BR112018013364A patent/BR112018013364A2/en not_active Application Discontinuation
- 2016-12-30 RU RU2018122825A patent/RU2018122825A/en not_active Application Discontinuation
- 2016-12-30 CN CN201680076626.8A patent/CN108473507A/en active Pending
- 2016-12-30 TW TW105144132A patent/TW201726686A/en unknown
- 2016-12-30 AU AU2016382385A patent/AU2016382385A1/en not_active Abandoned
- 2016-12-30 JP JP2018533946A patent/JP2019504046A/en not_active Withdrawn
- 2016-12-30 KR KR1020187018171A patent/KR20180089904A/en unknown
- 2016-12-30 US US16/066,341 patent/US10464946B2/en not_active Expired - Fee Related
- 2016-12-30 EP EP16882145.2A patent/EP3380482A4/en not_active Withdrawn
- 2016-12-30 SG SG11201804860YA patent/SG11201804860YA/en unknown
-
2018
- 2018-06-12 IL IL259982A patent/IL259982A/en unknown
- 2018-06-21 PH PH12018501331A patent/PH12018501331A1/en unknown
- 2018-09-20 HK HK18112173.4A patent/HK1252842A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW201726686A (en) | 2017-08-01 |
| CN108473507A (en) | 2018-08-31 |
| KR20180089904A (en) | 2018-08-09 |
| RU2018122825A3 (en) | 2020-02-28 |
| BR112018013364A2 (en) | 2018-12-04 |
| IL259982A (en) | 2018-07-31 |
| HK1252842A1 (en) | 2019-06-06 |
| MX2018008005A (en) | 2019-03-14 |
| AU2016382385A1 (en) | 2018-07-12 |
| US20190016733A1 (en) | 2019-01-17 |
| PH12018501331A1 (en) | 2019-02-18 |
| EP3380482A4 (en) | 2019-05-15 |
| JP2019504046A (en) | 2019-02-14 |
| RU2018122825A (en) | 2020-02-04 |
| US10464946B2 (en) | 2019-11-05 |
| EP3380482A1 (en) | 2018-10-03 |
| WO2017116193A1 (en) | 2017-07-06 |
| CA3010315A1 (en) | 2017-07-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201909278SA (en) | Fungicidal oxadiazoles | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201808878UA (en) | Heterocyclic compounds as ret kinase inhibitors | |
| SG11201810171SA (en) | Kras g12c inhibitors | |
| SG11201803686UA (en) | Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201807301SA (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201804811WA (en) | Fenfluramine compositions and methods of preparing the same | |
| SG11201909376TA (en) | Crystalline forms of a jak inhibitor compound | |
| SG11201408641UA (en) | Phenoxyethyl piperidine compounds | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201805368YA (en) | Anthelmintic depsipeptide compounds | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201909615YA (en) | Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same | |
| SG11201407546QA (en) | Novel ring-substituted n-pyridinyl amides as kinase inhibitors | |
| SG11201809830WA (en) | Selective reduction of cysteine-engineered antibodies | |
| SG11201407184PA (en) | Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib |